repaglinide

2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid

C27H36N2O4

http://purl.obolibrary.org/obo/dinto_DB00912

http://purl.obolibrary.org/obo/dinto_2153

68:20.16

A10BX02

135062-02-1

gluconorm

prandin

repaglinida [inn-spanish]

ag-ee 388 zw

repaglinidum [inn-latin]

ag-ee 623 zw

Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na?ve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.

http://purl.obolibrary.org/obo/OAE_0000453

http://purl.obolibrary.org/obo/OAE_0000236

http://purl.obolibrary.org/obo/OAE_0000377

http://purl.obolibrary.org/obo/OAE_0000198

http://purl.obolibrary.org/obo/OAE_0000406

http://purl.obolibrary.org/obo/OAE_0000567

http://purl.obolibrary.org/obo/OAE_0000415

http://purl.obolibrary.org/obo/OAE_0000195

http://purl.obolibrary.org/obo/OAE_0000210

http://purl.obolibrary.org/obo/OAE_0001448

http://purl.obolibrary.org/obo/OAE_0000660

http://purl.obolibrary.org/obo/OAE_0001025

http://purl.obolibrary.org/obo/OAE_0000600

http://purl.obolibrary.org/obo/OAE_0000403

http://purl.obolibrary.org/obo/OAE_0000454

http://purl.obolibrary.org/obo/OAE_0000601

http://purl.obolibrary.org/obo/OAE_0001463

http://purl.obolibrary.org/obo/OAE_0000498

http://purl.obolibrary.org/obo/OAE_0001057

http://purl.obolibrary.org/obo/OAE_0001200

http://purl.obolibrary.org/obo/OAE_0000584

http://purl.obolibrary.org/obo/OAE_0001129

http://purl.obolibrary.org/obo/OAE_0000414

http://purl.obolibrary.org/obo/OAE_0000038

http://purl.obolibrary.org/obo/OAE_0002122

http://purl.obolibrary.org/obo/OAE_0000780

http://purl.obolibrary.org/obo/OAE_0000385

http://purl.obolibrary.org/obo/OAE_0000468

http://purl.obolibrary.org/obo/OAE_0000602

http://purl.obolibrary.org/obo/OAE_0000779

http://purl.obolibrary.org/obo/OAE_0000374

http://purl.obolibrary.org/obo/OAE_0000462

http://purl.obolibrary.org/obo/OAE_0000358

http://purl.obolibrary.org/obo/OAE_0001458

http://purl.obolibrary.org/obo/OAE_0000350

http://purl.obolibrary.org/obo/dinto_2142

InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

InChIKey=FAEKWTJYAYMJKF-QHCPKHFHSA-N

http://purl.obolibrary.org/obo/dinto_2142

http://purl.obolibrary.org/obo/dinto_0901

http://purl.obolibrary.org/obo/dinto_0901

http://purl.obolibrary.org/obo/dinto_1221

http://purl.obolibrary.org/obo/dinto_2019

repaglinide

http://purl.obolibrary.org/obo/CHEBI_8214

http://purl.obolibrary.org/obo/CHEBI_5296

http://purl.obolibrary.org/obo/CHEBI_3437

http://purl.obolibrary.org/obo/dinto_DB01296

http://purl.obolibrary.org/obo/CHEBI_8499

http://purl.obolibrary.org/obo/CHEBI_4856

http://purl.obolibrary.org/obo/CHEBI_4031

http://purl.obolibrary.org/obo/CHEBI_63622

http://purl.obolibrary.org/obo/CHEBI_3127

http://purl.obolibrary.org/obo/dinto_DB00373

http://purl.obolibrary.org/obo/CHEBI_238698

http://purl.obolibrary.org/obo/CHEBI_3441

http://purl.obolibrary.org/obo/dinto_DB00582

http://purl.obolibrary.org/obo/CHEBI_2904

http://purl.obolibrary.org/obo/dinto_DB01359

http://purl.obolibrary.org/obo/CHEBI_5136

http://purl.obolibrary.org/obo/CHEBI_3732

http://purl.obolibrary.org/obo/CHEBI_6904

http://purl.obolibrary.org/obo/CHEBI_2379

http://purl.obolibrary.org/obo/CHEBI_3082

http://purl.obolibrary.org/obo/dinto_DB01580

http://purl.obolibrary.org/obo/dinto_DB00199

http://purl.obolibrary.org/obo/CHEBI_7444

http://purl.obolibrary.org/obo/CHEBI_31739

http://purl.obolibrary.org/obo/CHEBI_6343

http://purl.obolibrary.org/obo/CHEBI_8361

http://purl.obolibrary.org/obo/CHEBI_28077

http://purl.obolibrary.org/obo/CHEBI_258351

http://purl.obolibrary.org/obo/dinto_DB00976

obo2:dinto_DB00912

repaglinide

http://purl.obolibrary.org/obo/dinto_0217

CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O

2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid

C27H36N2O4

PharmGKB:PA451234

ChemSpider:59377

Drugs.com:http://www.drugs.com/cdi/repaglinide.html

RxList:http://www.rxlist.com/cgi/generic/prandin.htm

BindingDB:50153520

PubChem Compound:65981

PubChem Substance:46508150

National Drug Code Directory:35356-303-01

Wikipedia:http://en.wikipedia.org/wiki/Repaglinide

Drugs Product Database (DPD):2239925

PDRhealth:http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pra1343.shtml

http://purl.obolibrary.org/obo/dinto_000055